GlycoFi, Inc., a biotechnology company, develops a yeast-based protein optimization technology to develop, produce, and commercialize biotherapeutics. Its technology is based on a library of yeast strains that are engineered to perform specific human glycosylation at high fidelity. The company was founded in 2000 and is based in Lebanon, New Hampshire.

Contact Info: Lebanon, NH Exit: GlycoFi was acquired by Merck & Co in 2006